The first-of-its-kind AI-driven, non-blood-contact smart closed-loop diagnostic and treatment platform for heart conditions

Technology Platform - Advanced Soft-Robotic Cardiac Support Platform — A New Heart–Machine Interface

Our core invention - the Active Soft-Robotic Cardiac Support Device (ASD) - is an implantable hydraulic matrix designed to gently interface with the outer surface of the cardiac ventricle.

Why Is Cambridge CardioMatrix ASD a Disruptive Technology?

Key Features

• A hollow and interconnected flexible pipe network forms a heart-shaped soft robot network.

• Customisable internal fluid properties (viscosity, elasticity, pressure, drug type/dose) for personalised support.

• It also has the capability of 24-hour real-time monitoring, diagnosis and treatment intervention.

Intellectual Property: Breakthrough Patents

1. Cardiac Function Monitoring and/or Intervention System (Chinese Patent)

2. Active Hydraulic Ventricular Support System (United States Patent No. 9089425)

ASD：A Dual-Purpose Platform

• Clinical Platform: For real-time sensing and adaptive therapy in heart failure, myocarditis, congenital defects and more

• Research Platform: Provides brand-new tools for the research of cardiac biophysics, electromechanics and even quantum-level biological signals

The ASD platform represents a brand-new field: soft robot epicardial smart cardiac interface.

A New Paradigm for Cardiac Function Management

Advanced cardiac support solutions tailored to individual patient needs

Our technology uses a flexible hydraulic matrix that gently envelops the beating heart to enable：

• Full range of real-time sensing: capturing mechanical, electrophysiological, and biochemical signals of the heart.

• Soft-robotic assisted support: providing automated, controllable, and precise ventricular assistance—while entirely avoiding contact with circulating blood.

• Precise targeted intervention regulated by feedback: delivering immediate intervention through pressure modulation, electrical/magnetic stimulation or localised administration, latest biotechnology etc.

This integrative approach has the potential to fundamentally transform outcomes for patients with:

• Heart Failure

• Cardiomyopathies

• Post-myocardial infarction ventricular remodelling

• Congenital structural heart abnormalities

Cambridge CardioMatrix: Supporting the heart externally, letting the healing come from within...